Updated
Updated · The Pharmaceutical Journal · Jul 10
Large Trial Finds 3 Long-COVID Drug Classes Deliver Only Modest Short-Term Benefit
Updated
Updated · The Pharmaceutical Journal · Jul 10

Large Trial Finds 3 Long-COVID Drug Classes Deliver Only Modest Short-Term Benefit

3 articles · Updated · The Pharmaceutical Journal · Jul 10

Summary

  • Lancet Infectious Diseases published a large randomized controlled trial showing antihistamines, anti-inflammatory drugs and blood thinners produced only modest, short-term improvement in long COVID.
  • 5 to 6 years into the illness, many of the sickest patients still need effective treatments, underscoring why researchers and clinicians view large clinical trials as critical.
  • 10 weeks of cognitive rehabilitation in a separate small UCL-led trial helped some patients with symptoms such as brain fog make progress toward returning to work and hobbies.
  • Further trials are already in progress or planned, with researchers seeking stronger evidence and more durable options for a condition that remains disabling for many patients.

Insights

Why are community pharmacies, key to easing NHS pressure, excluded from the UK’s ten-year capital plan for healthcare?
Compounded semaglutide is ten times cheaper. Is it a safe alternative or a risky gamble for weight-loss patients?